Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
J Fish Biol ; 85(4): 1074-96, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25130320

ABSTRACT

This study evaluated Atlantic salmon Salmo salar smolt survival through the lower Penobscot River, Maine, U.S.A., and characterized relative differences in proportional use and survival through the main-stem of the river and an alternative migration route, the Stillwater Branch. The work was conducted prior to removal of two main-stem dams and operational changes in hydropower facilities in the Stillwater Branch. Survival and proportional use of migration routes in the lower Penobscot were estimated from multistate (MS) models based on 6 years of acoustic telemetry data from 1669 smolts and 2 years of radio-telemetry data from 190 fish. A small proportion (0·12, 95% c.i. = 0·06-0·25) of smolts used the Stillwater Branch, and mean survival through the two operational dams in this part of the river was relatively high (1·00 and 0·97). Survival at Milford Dam, the dam that will remain in the main-stem of the Penobscot River, was relatively low (0·91), whereas survival through two dams that were removed was relatively high (0·99 and 0·98). Smolt survival could decrease in the Stillwater Branch with the addition of two new powerhouses while continuing to meet fish passage standards. The effects of removing two dams in the main-stem are expected to be negligible for smolt survival based on high survival observed from 2005 to 2012 at those locations. Survival through Milford Dam was been well below current regulatory standards, and thus improvement of passage at this location offers the best opportunity for improving overall smolt survival in the lower river.


Subject(s)
Animal Migration , Power Plants , Salmo salar/physiology , Animal Identification Systems , Animals , Linear Models , Maine , Rivers , Telemetry
2.
Neurology ; 73(24): 2099-106, 2009 Dec 15.
Article in English | MEDLINE | ID: mdl-19907012

ABSTRACT

BACKGROUND: Statin use before surgery has been associated with reduced morbidity and mortality after vascular surgery. The effect of preoperative statin use on stroke and encephalopathy after coronary artery bypass grafting (CABG) is unclear. METHODS: A post hoc analysis was undertaken of a prospectively collected cohort of isolated CABG patients over a 10-year period at a single institution. Primary outcomes were stroke and encephalopathy. Univariable analyses identified risk factors for statin use, which were applied to a propensity score model using logistic regression and patients were divided into quintiles of propensity for statin use. Controlling for propensity score quintile, the odds ratio (OR) of combined stroke and encephalopathy (primary endpoint), cardiovascular mortality, myocardial infarction, and length of stay were compared between statin users and nonusers. RESULTS: There were 5,121 CABG patients, of whom 2,788 (54%) were taking statin medications preoperatively. Stroke occurred in 166 (3.2%) and encephalopathy in 438 (8.6%), contributing to 604 patients (11.8%) who met the primary endpoint. The unadjusted OR of stroke/encephalopathy in statin users was 1.053 (95% confidence interval [CI] 0.888-1.248, p = 0.582). Adjustment based on propensity score resulted in balance of stroke risk factors among quintiles. The propensity score-adjusted OR of stroke/encephalopathy in statin users was 0.958 (95% CI 0.784-1.170, p = 0.674). There were no significant differences in cardiovascular mortality, myocardial infarction, or length of stay between statin users and otherwise similar nonusers. CONCLUSIONS: In this large data cohort study, preoperative statin use was not associated with a decreased incidence of stroke and encephalopathy after coronary artery bypass grafting.


Subject(s)
Brain Diseases/prevention & control , Coronary Artery Bypass/adverse effects , Enzyme Inhibitors/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Preoperative Care , Stroke/prevention & control , Aged , Brain Diseases/epidemiology , Brain Diseases/etiology , Cohort Studies , Databases, Factual , Female , Humans , Incidence , Male , Middle Aged , Propensity Score , Prospective Studies , Stroke/epidemiology , Stroke/etiology , Treatment Failure
3.
Article in English | MEDLINE | ID: mdl-18076115

ABSTRACT

BACKGROUND: Chromium(III) is generally thought to be an essential trace element that allows for proper glucose metabolism. However, chromium(III) picolinate, Cr(pic)3, a popular dietary supplement form of chromium, has been shown to be capable of generating hydroxyl radicals and oxidative DNA damage in rats. The cation [Cr3O(O2CCH2CH3)(6(H2O)3]+, Cr3, has been studied as an alternative supplemental source of chromium. It has been shown to increase insulin sensitivity and lower glycated hemoglobin levels in rats, making it attractive as a potential therapeutic treatment for gestational diabetes. To date, no studies have been published regarding the safety of Cr3 supplementation to a developing fetus. METHODS: From gestation days (GD) 6-17, mated CD-1 female mice were fed diets delivering either 25 mg Cr/kg/day as Cr(pic)(3), 3.3 or 26 mg Cr/kg/day as Cr3, or the diet only to determine if Cr3 could cause developmental toxicity. Dams were sacrificed on GD 17, and their litters were examined for adverse effects. RESULTS: No signs of maternal toxicity were observed. No decrease in fetal weight or significantly increased incidence of skeletal defects was observed in the Cr3 or Cr(pic)3 exposed fetuses compared to the controls. CONCLUSION: Maternal exposure to either Cr(pic)3 or Cr3 at the dosages employed did not appear to cause deleterious effects to the developing offspring in mice.


Subject(s)
Dietary Supplements , Embryonic Development/drug effects , Fetal Development/drug effects , Organometallic Compounds/toxicity , Picolinic Acids/toxicity , Teratogens/toxicity , Administration, Oral , Animals , Dose-Response Relationship, Drug , Female , Maternal Exposure , Mice , Mice, Inbred Strains , Organometallic Compounds/classification , Picolinic Acids/classification , Pregnancy , Teratogens/classification
4.
Article in English | MEDLINE | ID: mdl-16767758

ABSTRACT

BACKGROUND: Chromium(III) picolinate, [Cr(pic)(3)], is a widely marketed dietary supplement. However, Cr(pic)(3) has been associated with oxidative damage to DNA in rats and mutations and DNA fragmentation in cell cultures. In isolated case reports, Cr(pic)(3) supplementation has been said to cause adverse effects, such as anemia, renal failure, liver dysfunction, and neuronal impairment. To date, no studies have been published regarding the safety of chromium picolinate supplementation to a developing fetus, although Cr(pic)(3) has been recommended for pregnant women who are diagnosed with gestational diabetes. METHODS: From gestation days (GD) 6-17, pregnant CD-1 mice were fed diets containing either 200 mg/kg Cr(pic)(3), 200 mg/kg CrCl(3), 174 mg/kg picolinic acid, or the diet only to determine if Cr(pic)(3), CrCl(3), or picolinic acid could cause developmental toxicity. Dams were sacrificed on GD 17, and their litters were examined for adverse effects. RESULTS: The incidence of bifurcated cervical arches was significantly increased in fetuses from the Cr(pic)(3) group as compared to the diet-only group. Fetuses in the picolinic acid-treated group had an incidence double that of the control group; however, this increase was not statistically significant. Fetuses in the CrCl(3) group did not differ from the controls in any variable examined. No maternal toxicity was observed in any of the treatment groups. CONCLUSIONS: High maternal oral exposures to chromium picolinate can cause morphological defects in developing offspring of mice.


Subject(s)
Abnormalities, Drug-Induced , Cervical Vertebrae/abnormalities , Cervical Vertebrae/drug effects , Picolinic Acids/toxicity , Animals , Cervical Vertebrae/embryology , Female , Mice , Pregnancy , Weight Gain/drug effects
5.
Neurology ; 65(7): 991-9, 2005 Oct 11.
Article in English | MEDLINE | ID: mdl-16107605

ABSTRACT

BACKGROUND: It is widely assumed that decline in cognition after coronary artery bypass grafting (CABG) is related to use of the cardiopulmonary bypass pump. Because most studies have not included comparable control groups, it remains unclear whether postoperative cognitive changes are specific to cardiopulmonary bypass, general aspects of surgery, or vascular pathologies of the aging brain. METHODS: This nonrandomized study included four groups: CABG patients (n = 140); off-pump coronary surgery (n = 72); nonsurgical cardiac controls (NSCC) with diagnosed coronary artery disease but no surgery (n = 99); and heart healthy controls (HHC) with no cardiac risk factors (n = 69). Subjects were evaluated at baseline (preoperatively), 3 months, and 12 months. Eight cognitive domains and a global cognitive score, as well as depressive and subjective symptoms were analyzed. RESULTS: At baseline, patients with coronary artery disease (CABG, off-pump, and NSCC) had lower performance than the HHC group in several cognitive domains. By 3 months, all groups had improved. From 3 to 12 months, there were minimal intrasubject changes for all groups. No consistent differences between the CABG and off-pump patients were observed. CONCLUSIONS: Compared with heart healthy controls (HHC), the groups with coronary artery disease had lower cognitive test scores at baseline. There was no evidence that the cognitive test performance of coronary artery bypass grafting (CABG) patients differed from that of control groups with coronary artery disease over a 1-year period. This study emphasizes the need for appropriate control groups for interpreting longitudinal changes in cognitive performance after CABG.


Subject(s)
Cerebrovascular Disorders/epidemiology , Cognition Disorders/epidemiology , Coronary Artery Bypass/adverse effects , Coronary Artery Disease/epidemiology , Heart-Lung Machine/adverse effects , Aged , Causality , Cerebrovascular Disorders/physiopathology , Clinical Trials as Topic/standards , Cognition Disorders/physiopathology , Cognition Disorders/psychology , Control Groups , Coronary Artery Bypass/instrumentation , Coronary Artery Disease/surgery , Data Interpretation, Statistical , Female , Humans , Hypoxia-Ischemia, Brain/epidemiology , Hypoxia-Ischemia, Brain/physiopathology , Male , Middle Aged , Neuropsychological Tests , Selection Bias , Time Factors
9.
Nursing ; 23(6): 60-1, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8510841
11.
Nursing ; 22(12): 64, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1465246
14.
16.
Article in English | MEDLINE | ID: mdl-1902514

ABSTRACT

Recombinant adenovirus vectors expressing the entire gag (p55) or CA (p24) region of human immunodeficiency virus type 1 (HIV-1) were constructed by inserting the appropriate HIV DNA sequences into the E3 region of human adenovirus type 5 (Ad5) with and without an exogenous SV40 early promoter. The infectious recombinant adenoviruses Adgag1, AdSVgag1, and AdSVCA1 were shown to express the appropriate HIV-1 antigens in human cells in vitro, as measured by immunoprecipitation and p24 antigen capture assays. Using the p24 antigen capture assay, HIV antigen expressed by AdSVCA1 was detected earlier in infection and in greater amounts than that produced by either Adgag1 or AdSVgag1. In studies concerning the immunogenicity of these vectors, Balb/c (H-2d) mice given a single intraperitoneal injection of 10(7) or 10(8) plaque-forming units of purified vector developed serum antibodies to p24, detected by Western blotting, by 2 weeks postinjection. In the preliminary test of the immunogenicity of the recombinant adenovirus vectors in primates, two of four rhesus macaque monkeys generated antibodies to HIV-1 p24 following two injections of AdSVCA1. As expected, monkeys injected with control adenovirus failed to show any anti-HIV response, and none of the monkeys showed any adverse reactions following infection with either recombinant or control adenoviruses. These results suggest that adenovirus vectors have considerable potential in the study of possible immune therapies for HIV infection.


Subject(s)
Adenoviruses, Human/genetics , Gene Products, gag/immunology , HIV Antibodies/biosynthesis , HIV-1/immunology , Protein Precursors/immunology , Viral Core Proteins/immunology , Viral Vaccines/immunology , Adenoviruses, Human/immunology , Animals , Antibodies, Viral/biosynthesis , DNA, Recombinant , Female , Gene Products, gag/genetics , Genetic Vectors , HIV Core Protein p24 , HIV-1/genetics , Immunization , Immunization, Secondary , Macaca mulatta , Mice , Mice, Inbred BALB C , Protein Precursors/genetics , Vaccines, Synthetic/immunology , Viral Core Proteins/genetics
17.
Aust Clin Rev ; 10(1): 7-17, 1990.
Article in English | MEDLINE | ID: mdl-2078151

ABSTRACT

OBJECTIVE: To review some of the problems associated with the prescription, supply and administration of drugs in a multicultural environment. METHOD: Staff questionnaire. RESULTS: Most respondents indicated the information received from the pharmacy was satisfactory, that they had read a recent therapeutic bulletin and that they could describe prescription handwriting as 'clear and reasonable'. There was general difficulty in understanding the meaning of Latin abbreviations and a demonstrated failure to absorb recently circulated information.


Subject(s)
Drug Information Services , Drug Prescriptions/standards , Personnel, Hospital , Pharmacy Service, Hospital , Culture , Humans , Interprofessional Relations , Language , United Arab Emirates , Writing
SELECTION OF CITATIONS
SEARCH DETAIL
...